Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to research if a type of biopsy known as sentinel lymph node biopsy (SLNB) can help in determining the rate of tumor deposits that are hard to detect and identify in node-negative cutaneous squamous cell carcinoma of the head or neck.
• Patients ≥ 18 years old at the time of informed consent
• Ability to provide written informed consent and HIPAA authorization
• Primary or recurrent invasive cutaneous squamous cell carcinoma of the head or neck, clinically staged T2-T4 based on AJCC staging
• Clinically and radiographically regional node-negative (no evidence of regional lymph node metastasis or distant metastasis)
• Able to undergo general anesthesia for sentinel lymph node biopsy
• Able to undergo CT scan with contrast or MRI with contrast
• Undergo surgical resection (Moh's or micrographic resection or standard excision with sentinel lymph node biopsy) within 8 weeks of imaging